Human Coagulation Factor 鈪� - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509240741

Publication Date:

September 19, 2024

Pages:

109

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Human Coagulation Factor 鈪� is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene result in hemophilia A, an X-linked coagulation disorder Human Coagulation Factor 鈪� is produced in liver sinusoidal cells and endothelial cells outside the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot.
The global market for Human Coagulation Factor 鈪� was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Coagulation Factor 鈪�, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Human Coagulation Factor 鈪� by region & country, by Type, and by Application.
The Human Coagulation Factor 鈪� market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Coagulation Factor 鈪�.
麻豆原创 Segmentation
By Company
Bayer
CSL Behring
Baxter
Grifols
Octapharma
Pfizer
Taibang Bio
Shanghai Laishi
Hualan Bio
Guangdong Shuanglin
GreenCross
Pfizer
Segment by Type:
Recombinant Factor VIII
Human Factor VIII
Segment by Application
Hemophilia A
Relvent Bleeding Diseases
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Human Coagulation Factor 鈪� manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Human Coagulation Factor 鈪� in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Human Coagulation Factor 鈪� in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Human Coagulation Factor 鈪� Product Introduction
1.2 Global Human Coagulation Factor 鈪� 麻豆原创 Size Forecast
1.3 Human Coagulation Factor 鈪� 麻豆原创 Trends & Drivers
1.3.1 Human Coagulation Factor 鈪� Industry Trends
1.3.2 Human Coagulation Factor 鈪� 麻豆原创 Drivers & Opportunity
1.3.3 Human Coagulation Factor 鈪� 麻豆原创 Challenges
1.3.4 Human Coagulation Factor 鈪� 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Coagulation Factor 鈪� Players Revenue Ranking (2023)
2.2 Global Human Coagulation Factor 鈪� Revenue by Company (2019-2024)
2.3 Key Companies Human Coagulation Factor 鈪� Manufacturing Base Distribution and Headquarters
2.4 Key Companies Human Coagulation Factor 鈪� Product Offered
2.5 Key Companies Time to Begin Mass Production of Human Coagulation Factor 鈪�
2.6 Human Coagulation Factor 鈪� 麻豆原创 Competitive Analysis
2.6.1 Human Coagulation Factor 鈪� 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Human Coagulation Factor 鈪� Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Coagulation Factor 鈪� as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Recombinant Factor VIII
3.1.2 Human Factor VIII
3.2 Global Human Coagulation Factor 鈪� Sales Value by Type
3.2.1 Global Human Coagulation Factor 鈪� Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Human Coagulation Factor 鈪� Sales Value, by Type (2019-2030)
3.2.3 Global Human Coagulation Factor 鈪� Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hemophilia A
4.1.2 Relvent Bleeding Diseases
4.2 Global Human Coagulation Factor 鈪� Sales Value by Application
4.2.1 Global Human Coagulation Factor 鈪� Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Human Coagulation Factor 鈪� Sales Value, by Application (2019-2030)
4.2.3 Global Human Coagulation Factor 鈪� Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Human Coagulation Factor 鈪� Sales Value by Region
5.1.1 Global Human Coagulation Factor 鈪� Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Human Coagulation Factor 鈪� Sales Value by Region (2019-2024)
5.1.3 Global Human Coagulation Factor 鈪� Sales Value by Region (2025-2030)
5.1.4 Global Human Coagulation Factor 鈪� Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Human Coagulation Factor 鈪� Sales Value, 2019-2030
5.2.2 North America Human Coagulation Factor 鈪� Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Human Coagulation Factor 鈪� Sales Value, 2019-2030
5.3.2 Europe Human Coagulation Factor 鈪� Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Human Coagulation Factor 鈪� Sales Value, 2019-2030
5.4.2 Asia Pacific Human Coagulation Factor 鈪� Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Human Coagulation Factor 鈪� Sales Value, 2019-2030
5.5.2 South America Human Coagulation Factor 鈪� Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Human Coagulation Factor 鈪� Sales Value, 2019-2030
5.6.2 Middle East & Africa Human Coagulation Factor 鈪� Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Coagulation Factor 鈪� Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Human Coagulation Factor 鈪� Sales Value
6.3 United States
6.3.1 United States Human Coagulation Factor 鈪� Sales Value, 2019-2030
6.3.2 United States Human Coagulation Factor 鈪� Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Human Coagulation Factor 鈪� Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Human Coagulation Factor 鈪� Sales Value, 2019-2030
6.4.2 Europe Human Coagulation Factor 鈪� Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Human Coagulation Factor 鈪� Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Human Coagulation Factor 鈪� Sales Value, 2019-2030
6.5.2 China Human Coagulation Factor 鈪� Sales Value by Type (%), 2023 VS 2030
6.5.3 China Human Coagulation Factor 鈪� Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Human Coagulation Factor 鈪� Sales Value, 2019-2030
6.6.2 Japan Human Coagulation Factor 鈪� Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Human Coagulation Factor 鈪� Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Human Coagulation Factor 鈪� Sales Value, 2019-2030
6.7.2 South Korea Human Coagulation Factor 鈪� Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Human Coagulation Factor 鈪� Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Human Coagulation Factor 鈪� Sales Value, 2019-2030
6.8.2 Southeast Asia Human Coagulation Factor 鈪� Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Human Coagulation Factor 鈪� Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Human Coagulation Factor 鈪� Sales Value, 2019-2030
6.9.2 India Human Coagulation Factor 鈪� Sales Value by Type (%), 2023 VS 2030
6.9.3 India Human Coagulation Factor 鈪� Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bayer
7.1.1 Bayer Profile
7.1.2 Bayer Main Business
7.1.3 Bayer Human Coagulation Factor 鈪� Products, Services and Solutions
7.1.4 Bayer Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.1.5 Bayer Recent Developments
7.2 CSL Behring
7.2.1 CSL Behring Profile
7.2.2 CSL Behring Main Business
7.2.3 CSL Behring Human Coagulation Factor 鈪� Products, Services and Solutions
7.2.4 CSL Behring Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.2.5 CSL Behring Recent Developments
7.3 Baxter
7.3.1 Baxter Profile
7.3.2 Baxter Main Business
7.3.3 Baxter Human Coagulation Factor 鈪� Products, Services and Solutions
7.3.4 Baxter Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.3.5 Grifols Recent Developments
7.4 Grifols
7.4.1 Grifols Profile
7.4.2 Grifols Main Business
7.4.3 Grifols Human Coagulation Factor 鈪� Products, Services and Solutions
7.4.4 Grifols Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.4.5 Grifols Recent Developments
7.5 Octapharma
7.5.1 Octapharma Profile
7.5.2 Octapharma Main Business
7.5.3 Octapharma Human Coagulation Factor 鈪� Products, Services and Solutions
7.5.4 Octapharma Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.5.5 Octapharma Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer Human Coagulation Factor 鈪� Products, Services and Solutions
7.6.4 Pfizer Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 Taibang Bio
7.7.1 Taibang Bio Profile
7.7.2 Taibang Bio Main Business
7.7.3 Taibang Bio Human Coagulation Factor 鈪� Products, Services and Solutions
7.7.4 Taibang Bio Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.7.5 Taibang Bio Recent Developments
7.8 Shanghai Laishi
7.8.1 Shanghai Laishi Profile
7.8.2 Shanghai Laishi Main Business
7.8.3 Shanghai Laishi Human Coagulation Factor 鈪� Products, Services and Solutions
7.8.4 Shanghai Laishi Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.8.5 Shanghai Laishi Recent Developments
7.9 Hualan Bio
7.9.1 Hualan Bio Profile
7.9.2 Hualan Bio Main Business
7.9.3 Hualan Bio Human Coagulation Factor 鈪� Products, Services and Solutions
7.9.4 Hualan Bio Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.9.5 Hualan Bio Recent Developments
7.10 Guangdong Shuanglin
7.10.1 Guangdong Shuanglin Profile
7.10.2 Guangdong Shuanglin Main Business
7.10.3 Guangdong Shuanglin Human Coagulation Factor 鈪� Products, Services and Solutions
7.10.4 Guangdong Shuanglin Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.10.5 Guangdong Shuanglin Recent Developments
7.11 GreenCross
7.11.1 GreenCross Profile
7.11.2 GreenCross Main Business
7.11.3 GreenCross Human Coagulation Factor 鈪� Products, Services and Solutions
7.11.4 GreenCross Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.11.5 GreenCross Recent Developments
7.12 Pfizer
7.12.1 Pfizer Profile
7.12.2 Pfizer Main Business
7.12.3 Pfizer Human Coagulation Factor 鈪� Products, Services and Solutions
7.12.4 Pfizer Human Coagulation Factor 鈪� Revenue (US$ Million) & (2019-2024)
7.12.5 Pfizer Recent Developments
8 Industry Chain Analysis
8.1 Human Coagulation Factor 鈪� Industrial Chain
8.2 Human Coagulation Factor 鈪� Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Coagulation Factor 鈪� Sales Model
8.5.2 Sales Channel
8.5.3 Human Coagulation Factor 鈪� Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bayer
CSL Behring
Baxter
Grifols
Octapharma
Pfizer
Taibang Bio
Shanghai Laishi
Hualan Bio
Guangdong Shuanglin
GreenCross
Pfizer

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.